share_log

Gilead Sciences | 10-Q: Q2 2024 Earnings Report

Gilead Sciences | 10-Q: Q2 2024 Earnings Report

吉利德科學 | 10-Q：2024財年二季報
美股SEC公告 ·  08/09 06:20

牛牛AI助理已提取核心訊息

Gilead Sciences reported Q2 2024 total revenues of $7.0 billion, up 5% year-over-year, driven by higher product sales in HIV, Oncology, and Liver Disease. Net income attributable to Gilead rose 55% to $1.6 billion, with diluted EPS increasing to $1.29 from $0.83 in Q2 2023. The growth was primarily due to lower operating expenses and higher revenues.HIV product sales grew 3% to $4.7 billion, with Biktarvy sales up 8%. Oncology sales increased 15%, led by a 23% rise in Trodelvy sales. Liver Disease product sales surged 17% to $832 million. However, Veklury sales declined 16% due to lower COVID-19 hospitalizations.For the first half of 2024, Gilead reported a net loss of $2.6 billion, compared to a $2.1 billion profit in H1 2023. This was largely due to a $3.9 billion acquired IPR&D charge related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge. The company ended Q2 with $2.8 billion in cash and equivalents, down from $8.4 billion at 2023 year-end, primarily due to the CymaBay acquisition and debt repayments.
Gilead Sciences reported Q2 2024 total revenues of $7.0 billion, up 5% year-over-year, driven by higher product sales in HIV, Oncology, and Liver Disease. Net income attributable to Gilead rose 55% to $1.6 billion, with diluted EPS increasing to $1.29 from $0.83 in Q2 2023. The growth was primarily due to lower operating expenses and higher revenues.HIV product sales grew 3% to $4.7 billion, with Biktarvy sales up 8%. Oncology sales increased 15%, led by a 23% rise in Trodelvy sales. Liver Disease product sales surged 17% to $832 million. However, Veklury sales declined 16% due to lower COVID-19 hospitalizations.For the first half of 2024, Gilead reported a net loss of $2.6 billion, compared to a $2.1 billion profit in H1 2023. This was largely due to a $3.9 billion acquired IPR&D charge related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge. The company ended Q2 with $2.8 billion in cash and equivalents, down from $8.4 billion at 2023 year-end, primarily due to the CymaBay acquisition and debt repayments.
吉利德科學在2024年第二季度報告的總收入爲70億元，同比增長5%，主要受到HIV、腫瘤學和肝病產品銷售增長的推動。歸屬於吉利德的凈利潤增長了55%，達到16億元，攤薄後每股收益從2023年第二季度的0.83美元增加到1.29美元。增長主要得益於營業費用降低和收入增加。HIV產品銷售增長3%，達到47億元，Biktarvy銷售增長了8%。腫瘤學銷售增長15%，Trodelvy銷售增長23%是主要驅動因素。肝病產品銷售激增17%，達到83200萬元。然而，由於COVID-19住院人數減少，Veklury的銷售下降了16%。在2024年上半年，吉利德報告淨虧損26億元，而2023年上半年則盈利21億元。這主要是由於與CymaBay收購相關的39億元的知識產權研發費用和24億元的知識產權研發減值費用。公司在第二季度結束時現金及等價物爲28億元，較2023年年末的84億元減少，主要是由於CymaBay收購和債務償還。
吉利德科學在2024年第二季度報告的總收入爲70億元，同比增長5%，主要受到HIV、腫瘤學和肝病產品銷售增長的推動。歸屬於吉利德的凈利潤增長了55%，達到16億元，攤薄後每股收益從2023年第二季度的0.83美元增加到1.29美元。增長主要得益於營業費用降低和收入增加。HIV產品銷售增長3%，達到47億元，Biktarvy銷售增長了8%。腫瘤學銷售增長15%，Trodelvy銷售增長23%是主要驅動因素。肝病產品銷售激增17%，達到83200萬元。然而，由於COVID-19住院人數減少，Veklury的銷售下降了16%。在2024年上半年，吉利德報告淨虧損26億元，而2023年上半年則盈利21億元。這主要是由於與CymaBay收購相關的39億元的知識產權研發費用和24億元的知識產權研發減值費用。公司在第二季度結束時現金及等價物爲28億元，較2023年年末的84億元減少，主要是由於CymaBay收購和債務償還。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間